Fortrea Holdings Inc. (FTRE) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Fortrea Holdings Inc. (FTRE) stock forecast summary
On Oct. 16, 2026, FTRE is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5184 stocks scored that day.
Fortrea Holdings Inc. is a mid-cap company with a market capitalization of $2.14B. It ranks number 12 by market capitalization among the 29 Services-Medical Laboratories issuers in our coverage with a current forecast.
For FTRE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 44.0%, measured on 302 forecast dates between 2023-08-18 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 37.0%, measured on 345 forecast dates between 2023-08-18 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, FTRE included.
Follow FTRE freeFTRE price chart and AI forecast
How FTRE ranks among 5184 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fortrea Holdings Inc. (FTRE) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | FTRE | Rank |
|---|---|---|
| Market Cap | $2.14B | 12/29 |
| P/B Ratio | 4.08x | 8/22 |
| EPS | $-0.56 | – |
| Book Value/Share | $5.51 | – |
| Revenue/Share | $28.14 | – |
| FCF/Share | $2.06 | – |
Profitability & Margins
| Metric | FTRE | Rank |
|---|---|---|
| ROIC | -0.6% | 9/24 |
| Gross Margin | 19.3% | 8/16 |
| Operating Margin | -0.4% | 9/23 |
| EBT Margin | -2.9% | 9/23 |
| Tax Rate | -9.5% | – |
Financial Health
| Metric | FTRE | Rank |
|---|---|---|
| Current Ratio | 0.96x | 22/26 |
| D/E Ratio | 4.18x | 2/22 |
| Financial Leverage | 5.18x | 2/22 |
| Interest Coverage | 0.5x | 6/23 |
| Working Capital | -$40M | 26/26 |
Cash Flow
| Metric | FTRE | Rank |
|---|---|---|
| Operating Cash Flow | $228M | 5/27 |
| Free Cash Flow | $196M | 3/17 |
| Capital Spending | -$32M | 11/17 |
| FCF/Sales | 7.3% | 6/16 |
| CapEx/Sales | 1.2% | 14/16 |
Operational Efficiency
| Metric | FTRE | Rank |
|---|---|---|
| Asset Turnover | 0.99x | 4/18 |
| Receivables Turnover | 17.7x | 1/19 |
| Days Sales Outstanding | 21 days | 19/19 |
| Payables Period | 9 days | 13/14 |
Income Statement
| Metric | FTRE | Rank |
|---|---|---|
| Total Revenue | $2.68B | 3/19 |
| Operating Income | -$11M | 13/26 |
| SG&A Expense | $412M | 6/20 |
| Cost of Goods Sold | $2.16B | 3/15 |
Dividend & Shareholder Information
| Metric | FTRE | Rank |
|---|---|---|
| Shares Outstanding | 95M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $924M | 34.0% of assets |
| Cash & Short-term Investments | $169M | 6.2% of assets |
| Accounts Receivable | $151M | 5.6% of assets |
| Total Liabilities | $2.19B | 80.7% of assets |
| Short-term Debt | $910M | 33.5% of assets |
FTRE quarterly financials and insider trading
Fortrea Holdings Inc. (FTRE) industry peers
Companies classified under the same SEC industry code as Fortrea Holdings Inc. (Services-Medical Laboratories): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| FTRE Fortrea Holdings Inc. | ▶ | $2.14B |
| NTRA Natera, Inc. | ▲ | $56.71B |
| DGX Quest Diagnostics Inc | ▼ | $25.94B |
| LH Labcorp Holdings Inc. | ▶ | $25.79B |
| GH Guardant Health, Inc. | ▲ | $21.28B |
| CAI Caris Life Sciences, Inc. | ▲ | $8.64B |
| RDNT Radnet, Inc. | ▶ | $5.41B |
| GRAL Grail, Inc. | ▲ | $5.26B |
| BLLN Billiontoone, Inc. | ▲ | $4.63B |
| VCYT Veracyte, Inc. | ▲ | $3.47B |
| CDNA Caredx, Inc. | ▲ | $3.31B |
| CELC Celcuity Inc. | ▲ | $2.77B |
| PSNL Personalis, Inc. | ▼ | $1.67B |
| FRNM Freenome, Inc. | ▶ | $1.26B |
| LMRI Lumexa Imaging Holdings, Inc. | ▶ | $1.04B |
| CSTL Castle Biosciences Inc | ▲ | $976M |
| FLGT Fulgent Genetics, Inc. | ▲ | $545M |
| BDSX Biodesix Inc | ▲ | $250M |
| XGN Exagen Inc. | ▲ | $187M |
| BNR Burning Rock Biotech Ltd | ▲ | $139M |
| SERA Sera Prognostics, Inc. | ▼ | $80M |
| CFOR Capforce Inc. | ▶ | $43M |
| MDXH Mdxhealth Sa | ▲ | $20M |
| AMS American Shared Hospital Services | ▼ | $9M |
| ADVB Advanced Biomed Inc. | ▶ | $7M |
| ACON Aclarion, Inc. | ▲ | $5M |
| BGLC Bionexus Gene Lab Corp | ▲ | $4M |
| LUDG Ludwig Enterprises, Inc. | ▼ | $670K |
| FCHS First Choice Healthcare Solutions, Inc. | ▶ | $260K |
| RNLXY Renalytix Plc | ▲ | N/A |
Where FTRE sits on the market map
Fortrea Holdings Inc. (FTRE) stock news
Loading...
Fortrea Holdings Inc. (FTRE) stock forecast FAQ
What is the Fortrea Holdings Inc. (FTRE) stock forecast?
On Oct. 16, 2026, FTRE is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5184 stocks scored that day.
How accurate are Fortrea Holdings Inc. stock predictions?
For FTRE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 44.0%, measured on 302 forecast dates between 2023-08-18 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 37.0%, measured on 345 forecast dates between 2023-08-18 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Fortrea Holdings Inc. forecasts updated?
Fortrea Holdings Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Fortrea Holdings Inc.'s industry peers?
30 issuers in our coverage, FTRE included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Quest Diagnostics Inc (DGX), Labcorp Holdings Inc. (LH), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Radnet, Inc. (RDNT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.